# Handok Inc.

Organization · id `cardio:org-handok-inc` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov sponsor names](<https://clinicaltrials.gov/search?spons=Handok+Inc.>), retrieved 18 November 2026. No person wrote or checked this page.

## In plain language

An organization that ClinicalTrials.gov lists as a sponsor or collaborator of 10 trials in this atlas.

## Technical summary

Sponsor class industry. No ROR record matches the name exactly.

## The registry's words

- Sponsor name: Handok Inc.
- Sponsor class: INDUSTRY

## Connected pages

- Sponsors: Compare the Compliance of Patients Treated With Once-daily (od) or Twice-daily (Bid) Glimepiride and Metformin Fixed Combination Therapy (`cardio:ct-nct01444248`)
- Sponsors: Teneligliptin(MP-513) Versus Placebo in Type 2 Diabetes Mellitus (`cardio:ct-nct01798238`)
- Sponsors: Teneligliptin(MP-513) vs. Placebo in Patient With Metformin Monotherapy (`cardio:ct-nct01805830`)
- Sponsors: Tenelia Triple Combination Study (`cardio:ct-nct02567994`)
- Sponsors: Phase 2 Study to Evaluate the Efficacy and Safety of Irbesartan and Amlodipine Combined or Alone in Patients With Essential Hypetension (`cardio:ct-nct04488978`)
- Sponsors: Clinical Efficacy and Safety Evaluation of Irbesartan High and Amlodipine Combined Therapy in Essential Hypertension Patients (`cardio:ct-nct05475665`)
- Sponsors: Clinical Efficacy and Safety Evaluation of Irbesartan and Amlodipine Combined Therapy in Essential Hypertension Patients (`cardio:ct-nct05476354`)
- Sponsors: Clinical Efficacy and Safety Evaluation of Teneligliptin in Type 2 Diabetes Who Have Inadequate GlycemIc Control With Empaglyflozin 25 mg and Metformin (`cardio:ct-nct05504226`)
- Sponsors: Clinical Efficacy and Safety Evaluation of Teneligliptin in Type 2 Diabetes Who Have Inadequate GlycemIc Control With Empaglyflozin and Metformin (`cardio:ct-nct05504239`)
- Sponsors: A Registry-based Randomized Controlled Trial in Type 2 Diabetes With Cardiovascular Risk Factors (REMATCH) (`cardio:ct-nct06627322`)

## Provenance

Content hash: 188b1314ed981deb56f69f6954a981b598f0333282350c9a6bab0140bdd74d17
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
